AMNEAL PHARMACEUTICALS, INC. Deferred Federal Income Tax Expense (Benefit)
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Deferred Federal Income Tax Expense (Benefit) of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2022-03-01
- AMNEAL PHARMACEUTICALS, INC. deferred federal income tax expense (benefit) for fiscal 2021 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. deferred federal income tax expense (benefit) for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- AMNEAL PHARMACEUTICALS, INC. deferred federal income tax expense (benefit) for fiscal 2019 was $365.55M.
- AMNEAL PHARMACEUTICALS, INC. deferred federal income tax expense (benefit) for fiscal 2018 was -$2.97M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-01 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-01 |
| 2019-12-31 | $365.55M 10-K · filed 2022-03-01 |
| 2018-12-31 | -$2.97M 10-K · filed 2021-03-01 |
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 |
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |